Rifampicin and its clinical use
Fafrowicz, B.
Wiadomosci Lekarskie 24(3): 233-238
1971
ISSN/ISBN: 0043-5147 PMID: 4926926 Document Number: 31772
Document emailed within 1 workday
Related Documents
Tamura, M.; Yamazaki, A.; Tamura, T.; Takano, S.; Yamazaki, M. 1973: The critical concentration of clinical rifampicin resistance for tubercle bacilli and the acquirement pattern of rifampicin resistance of tubercle bacilli on Kirchner's semi-liquid agar media Kekkaku: 48(6): 247-253Medoff, G.; Kwan, C.N.; Schlessinger, D.; Kobayashi, G.S. 1973: Potentiation of rifampicin, rifampicin analogs, and tetracycline against animal cells by amphotericin B and polymyxin B Cancer Research 33(6): 1146-1149
Rossolini, A.; Cellesi, C.; Debolini, A. 1973: Experimental study of liver damage due to rifampicin and rifampicin-isoniazid combination Il Farmaco; Edizione Pratica 28(6): 345-355
Poupon, R.Y.; Meyniel, D.; Petit, J.; Gustot, P.; Darnis, F. 1979: Cholestatic hepatitis during treatment with I.N.H. and rifampicin: arguments in favour of the hepatotoxicity of rifampicin Annales de Medecine Interne 130(6-7): 371-375
Saltoglu, N.; Tasova, Y.; Inal, A.S.; Seki, T.; Aksu, H.S. 2002: Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis Saudi Medical Journal 23(8): 921-924
Panchagnula, R.; Singh, I.; Kaur, K.J.; Kaul, C.L. 1999: Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations Methods and Findings in Experimental and Clinical Pharmacology 21(9): 625-628
Reimers, D. 1971: Malformations caused by rifampicin? 2 cases of normal fetal development after rifampicin treatment in early pregnancy Münchener Medizinische Wochenschrift 113(50): 1690-1691
Acocella, G.; Segre, G. 1974: Kinetics of rifampicin and desacetyl-rifampicin in plasma, bile, and urine in humans and the effect of repeated administrations Acta Pharmaceutica Suecica 11(6): 657-658
Bhatt, A.D.; Vaz, J.A.; Padgaonkar, K.A. 1998: Clinical relevance of reduced bioavailability of rifampicin Journal of the Association of Physicians of India 46(8): 729-731
1999: From the Clinical Effectiveness Committee. Use of rifampicin and contraceptive steroids British Journal of Family Planning 24(4): 169-170
Tsubota, N.; Tanimukai, S. 2015: A Clinical Experience of Rifampicin Suppository for the Treatment of Pulmonary Tuberculosis Kekkaku: 90(6): 543-547
Silva, J.; Herrera, N.; Becerra, S.; Jofré, M.; Gutiérrez, A.; Hannelore 1981: Comparative in vitro activity of aminoglycosides and rifampicin upon bacteria from clinical specimens Revista Medica de Chile 109(3): 231-235
Vartanian, Z.S. 1973: The eliminating effect of rifampicin and acriflavine on the determinants of antibiotics resistance in clinical strains of staphylococcus Antibiotiki 18(11): 994-997
Generozov, E.V.; Al'tshuler, M.L.; Govorun, V.M.; Lopukhin, I.M.; Golyshevskaia, V.I.; Chernousova, L.N.; Khomenko, A.G. 1999: Detection and characteristics of rpoB gene mutations in rifampicin-resistant clinical strains of M. tuberculosis Problemy Tuberkuleza 2: 39-42
González, N.; Torres, M.J.; Palomares, J.C.; Aznar, J. 1998: Characterization of the rpoB gene mutations in clinical isolates of rifampicin-resistant Mycobacterium tuberculosis Enfermedades Infecciosas y Microbiologia Clinica 16(9): 404-407
Coban, A.Y.; Bilgin, K.; Uzun, M.; Durupinar, B. 2009: Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates Mikrobiyoloji Bulteni 43(2): 293-297
Camacho, A.; Pérez-Camacho, I.és.; Rivero, A.; Natera, C.; García-Lázaro, M.; Castón, J.J.é; Gallo, M.; Kindelán, J.é M.ía.; Torre-Cisneros, J.án. 2010: Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials Enfermedades Infecciosas y Microbiologia Clinica 28(4): 239-244
Woo, J.; Chan, C.; Chan, R.; Cheung, W.; Or, K.; Chan, K. 1995: Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters Journal of Medicine 26(5-6): 279-294
Patel, N.; Jagannath, K.; Vora, A.; Patel, M.; Patel, A. 2017: A Randomized, Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Tolerability of Risorine with Conventional Rifampicin in the Treatment of Newly Diagnosed Pulmonary Tuberculosis Patients Journal of the Association of Physicians of India 65(9): 48-54
Wehrlin, N. 1972: Rifampicin Revue de l'Infirmiere 22(5): 507-510